STOCKHOLM, Sweden, 27th October 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that the company has filed a new patent application with the European Patent Office (EPO). The patent originates from the development that took place during the reformulation work with AKP02, now AKP02G2.

In line with Lipidor's strategy, the company continuously reviews and works to further strengthen and expand patent protection for its AKVANO®-technology. The new patent application is based on the development work carried out over the past year, which led to an updated formulation of the company's most important drug candidate for the treatment of psoriasis, AKP02G2. The new patent application (a so-called priority application) was filed with the European Patent Office (EPO) on October 27, 2023, and also covers the use of the formulation technology in other treatment areas.

“In AKP02G2, the interaction of the formulation with the different layers of the skin has been optimized, which we expect will lead to an improvement in the deposition and efficacy of the active substances,” said Jan Holmbäck, CSO at Lipidor.

With the new patent application, AKP02G2 and a number of other applications of the technology (subject to approval by the patent authorities) will be patent protected until 2044.

“We already have solid patent protection, but of course we are very positive about the opportunities that are opened up through potentially strengthening and extending protection for our technology,” says Ola Holmlund, CEO of Lipidor. “The patent application protects the development investments that have been made and if the application is approved, it is very likely to generate commercial value.”

Publication
The information was provided for publication by Lipidor’s CEO on 27 October 2023 at 9.45 am (CEST).

For more information, please contact:

Ola Holmlund, CEO
Telephone: +46 (0) 72 50 70 369
Email: ola.holmlund@lipidor.se

The company´s Certified Adviser is Erik Penser Bank AB.

About Lipidor AB
Lipidor AB (www.lipidor.se) is a pharmaceutical development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The company can develop topical medical products for the treatment of diseases such as psoriasis, acne vulgaris, bacterial skin infections and atopic dermatitis by reformulation of proven pharmaceutical substances. Lipidor’s priority project is AKP02G2, which focusses on psoriasis.

About AKVANO®
AKVANO® is an innovative water-free and sprayable technology for formulating medicines and is particularly suitable for local application on, for example, the skin. AKVANO® is made up of carefully selected lipids which, together with a volatile solvent, form the carrier of selected active substances. By combining different lipids, AKVANO® can be optimized to achieve the desired function of active components in the formulation. When applied to the skin, the solvent evaporates and a thin lipid layer is formed on the skin surface for effective release of the active substance.

Lipidor's formulation platform (AKVANO®) has broad patent protection in the form of five patent families filed between 2009 and 2023. To date, 27 patents have been granted, while 7 patent applications are under review.

Attachments
Lipidor submits new patent application

© Modular Finance, source Nordic Press Releases